HIV/AIDS Therapy

Positive Thiovir data presented at IAS 2005 conference

Published in Drug Week, September 2nd, 2005

Adventrx Pharmaceuticals, Inc., (ANX) announced data from an in vitro study indicating that Thiovir, the company's non-nucleoside reverse transcriptase inhibitor (NNRTI), demonstrated effectiveness against human immunodeficiency virus type-1 (HIV-1), which is resistant to other NNRTIs and nucleoside reverse transcriptase inhibitors (NRTIs).

Thiovir also exhibited a slightly higher level of antiviral activity against HIV-1 than foscarnet, a currently marketed, broad spectrum antiviral indicated for treatment of opportunistic infections in HIV patients. A poster of the study data was presented at the 3rd International AIDS Society Conference (IAS 2005) on HIV Pathogenesis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-09-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry